Видео ютуба по тегу Car-T Consolidation

Risks and indications for consolidation alloHSCT after CAR T-cell therapy in ALL
Risks and indications for consolidation alloHSCT after CAR T-cell therapy in ALL
Can CD30 CAR T-cell consolidation improve outcomes after ASCT for patients with CD30+ lymphomas?
Can CD30 CAR T-cell consolidation improve outcomes after ASCT for patients with CD30+ lymphomas?
Benefits of post CAR-T alloHSCT consolidation therapy in B-ALL
Benefits of post CAR-T alloHSCT consolidation therapy in B-ALL
Moving CAR T-cell therapy and bispecific antibodies in the consolidation setting
Moving CAR T-cell therapy and bispecific antibodies in the consolidation setting
STEM Trial: Cevostamab Consolidation Sustains MRD Negativity After CAR-T in Multiple Myeloma
STEM Trial: Cevostamab Consolidation Sustains MRD Negativity After CAR-T in Multiple Myeloma
Loncastuximab tesirine as a consolidation strategy post-CAR T-cell therapy in DLBCL
Loncastuximab tesirine as a consolidation strategy post-CAR T-cell therapy in DLBCL
The promise of CAR-T therapy in adult ALL and future outlooks
The promise of CAR-T therapy in adult ALL and future outlooks
Optimizing preceding and consolidation therapies to prevent post-CAR-T relapse in B-ALL
Optimizing preceding and consolidation therapies to prevent post-CAR-T relapse in B-ALL
Using Cevostamab Consolidation After CAR-T to Improve Outcomes | Adam Cohen, MD | #IMS25 #myeloma
Using Cevostamab Consolidation After CAR-T to Improve Outcomes | Adam Cohen, MD | #IMS25 #myeloma
CAR-T Therapy (ide-cel) Consolidation for Suboptimal ASCT Responders | Barry Paul, MD | #ASH24
CAR-T Therapy (ide-cel) Consolidation for Suboptimal ASCT Responders | Barry Paul, MD | #ASH24
GoCART ongoing projects: impact of prior therapy & alloSCT consolidation on CAR-T outcomes in ALL
GoCART ongoing projects: impact of prior therapy & alloSCT consolidation on CAR-T outcomes in ALL
Which factors influence the need for allo-SCT consolidation in patients treated with CAR T-cells?
Which factors influence the need for allo-SCT consolidation in patients treated with CAR T-cells?
Autologous or allogeneic stem cell transplant for consolidation therapy in T-cell lymphomas?
Autologous or allogeneic stem cell transplant for consolidation therapy in T-cell lymphomas?
Positioning CAR T-cell therapy for hematological malignancies
Positioning CAR T-cell therapy for hematological malignancies
CAR-T in myeloma: what is the potential?
CAR-T in myeloma: what is the potential?
AATT study final results: allo or auto transplant for consolidation in T-cell lymphoma?
AATT study final results: allo or auto transplant for consolidation in T-cell lymphoma?
Future avenues for CAR T-cell therapy in ALL
Future avenues for CAR T-cell therapy in ALL
How to optimize CAR-T therapy for ALL
How to optimize CAR-T therapy for ALL
ASH23: STEM Trial Study on Cevostamab Consolidation After BCMA CAR T-Cell Therapy | Adam Cohen, MD
ASH23: STEM Trial Study on Cevostamab Consolidation After BCMA CAR T-Cell Therapy | Adam Cohen, MD
Hemogenyx CEO and director on share consolidation, CAR-T advancements & CBR breakthroughs
Hemogenyx CEO and director on share consolidation, CAR-T advancements & CBR breakthroughs